Abstract
SIGNALLING by all-trans retinoic acid is mediated through RXR-RAR retinoid receptor heterodimers1,2, in which RXR has been considered to act as a transcriptionally silent partner3–5. However, we show here that in cultured NB4 (ref. 6) human acute promyelocytic leukaemia7–9 cells treated with either an RAR-α-selective agonist alone, or certain RAR-α antagonists in combination with an RXR agonist, receptor–DNA binding is induced in vivo, resulting in expression of the target genes of retinoic acid as well as acute promyelocytic leukaemia protein (PML) relocation to nuclear bodies10–12 and differentiation before apoptosis. These results indicate that RAR-α ligands can induce two separate events: one enables RXR–RAR-α heterodimers to bind to DNA in vivo and allows RXR agonists to act; the other induces transcriptional activity of RAR-α. The availability of receptor-specific synthetic retinoids that can induce distinct receptor functions has potential in extending the therapeutic repertoire of retinoids.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gronemeyer, H. & Laudet, V. Protein Profile 2, 1173–1308 (1985).
Chambon, P. FASEB J. (in the press).
Kurokawa, R. et al. Nature 371, 528–531 (1994).
Forman, B. M., Umesono, K., Chen, J. & Evans, R. M. Cell 81, 541–550 (1995).
Mangelsdorf, D. J. & Evans, R. M. Cell 83, 835–850 (1995).
Lanotte, M. et al. Blood 77, 1080–1086(1991).
Warrel, R. P. et al. N. Engl. J. Med. 329, 177–189 (1993).
Grignani, F. et al. Blood 83, 10–25 (1994).
Lavau, C. & Dejean, A. Leukemia 8, 1615–1621 (1994).
Dyck, J. A. et al. Cell 76, 333–343 (1994).
Weis, K. et al. Cell 76, 345–358 (1994).
Koken, M. H. et al. EMBO J. 13, 1073–1083 (1994).
Chen, J-Y. et al. EMBO J. 14, 1187–1197 (1995).
Lehmann, J. M. et al. Science 258, 1944–1946 (1992).
Roy, B., Taneja, R. & Chambon, P. Mol. Cell. Biol. 15, 6481–6487 (1995).
Taneja, R. et al. Proc. Natl Acad. Sci. USA 93, 6197–6202 (1996).
Grignani, F. et al. Cell 74, 423–431 (1993).
Valcarcel, R., Holz, H., Jiminez, C. G., Barettino, D. & Stunnenberg, H. G. Genes Dev. 8, 3068–3079 (1994).
Dey, A., Minucci, S. & Ozato, K. Mol. Cell. Biol. 14, 8191–8201 (1994).
Kersten, S., Dawson, M. I., Lewis, B. A. & Noy, N. Biochemistry 35, 3816–3824 (1996).
Apfel, R. et al. J. Biol. Chem. 270, 30765–30772 (1995).
Durand, B. et al. Cell 71, 73–85 (1992).
Blanco, J. C. G. et al. Genes to Cells 1, 209–211 (1996).
Clifford, J. et al. EMBO J. (in the press).
Nagy, L. et al. Mol. Cell. Biol. 15, 3540–3551 (1995).
Mueller, P. R. & Wold, B. Science 246, 780–786 (1989).
Garrity, P. A. & Wold, B. J. Proc. Natl Acad. Sci. USA 89, 1021–1025 (1992).
Nagpal, S., Friant, S., Nakshatri, H. & Chambon, P. EMBO J. 12, 2349–2360 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, JY., Clifford, J., Zusi, C. et al. Two distinct actions of retinoid-receptor ligands. Nature 382, 819–822 (1996). https://doi.org/10.1038/382819a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/382819a0
- Springer Nature Limited
This article is cited by
-
The Retinoid Agonist Tazarotene Promotes Angiogenesis and Wound Healing
Molecular Therapy (2016)
-
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
British Journal of Cancer (2012)
-
Dissecting the retinoid‐induced differentiation of F9 embryonal stem cells by integrative genomics
Molecular Systems Biology (2011)
-
A structural view of nuclear hormone receptor: endocrine disruptor interactions
Cellular and Molecular Life Sciences (2010)
-
New insights into the role of PML in tumour suppression
Cell Research (2008)